Lowest-Rated StocksLowest-RatedNYSE:NVTA Invitae (NVTA) Stock Forecast, Price & News $1.19 -0.05 (-4.03%) (As of 06/7/2023 ET) Add Compare Share Share Today's Range$1.18▼$1.2650-Day Range$1.05▼$1.6352-Week Range$1.02▼$9.00Volume6.04 million shsAverage Volume8.45 million shsMarket Capitalization$310.20 millionP/E RatioN/ADividend YieldN/APrice Target$3.88 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Invitae MarketRank™ ForecastAnalyst RatingHold1.55 Rating ScoreUpside/Downside226.3% Upside$3.88 Price TargetShort InterestBearish18.37% of Shares Sold ShortDividend StrengthN/ASustainability-1.15Upright™ Environmental ScoreNews Sentiment0.56Based on 3 Articles This WeekInsider TradingSelling Shares$198,630 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.48) to ($1.14) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.06 out of 5 starsMedical Sector394th out of 981 stocksMedical Laboratories Industry10th out of 22 stocks 2.8 Analyst's Opinion Consensus RatingInvitae has received a consensus rating of Hold. The company's average rating score is 1.55, and is based on no buy ratings, 6 hold ratings, and 5 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.88, Invitae has a forecasted upside of 226.3% from its current price of $1.19.Amount of Analyst CoverageInvitae has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted18.37% of the outstanding shares of Invitae have been sold short.Short Interest Ratio / Days to CoverInvitae has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in Invitae has recently decreased by 4.16%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldInvitae does not currently pay a dividend.Dividend GrowthInvitae does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInvitae has received a 70.96% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Private genetic testing services" and "Diagnostic test kits" products. See details.Environmental SustainabilityThe Environmental Impact score for Invitae is -1.15. Previous Next 2.0 News and Social Media Coverage News SentimentInvitae has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Invitae this week, compared to 4 articles on an average week.Search InterestOnly 30 people have searched for NVTA on MarketBeat in the last 30 days. This is a decrease of -23% compared to the previous 30 days.MarketBeat Follows12 people have added Invitae to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Invitae insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $198,630.00 in company stock.Percentage Held by InsidersOnly 1.10% of the stock of Invitae is held by insiders.Percentage Held by Institutions76.79% of the stock of Invitae is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Invitae are expected to grow in the coming year, from ($1.48) to ($1.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Invitae is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Invitae is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInvitae has a P/B Ratio of 2.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Invitae (NYSE:NVTA) StockInvitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.Read More Receive NVTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Invitae and its competitors with MarketBeat's FREE daily newsletter. Email Address NVTA Stock News HeadlinesJune 6, 2023 | americanbankingnews.comInvitae Co. (NYSE:NVTA) Receives $2.33 Average Price Target from AnalystsJune 5, 2023 | msn.comWall Street Says These 2 Stocks May Double. Should You Buy Them?June 8, 2023 | Edge On The Street (Ad)The Real Problem With "Made in America" LithiumPoliticians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple. May 31, 2023 | finance.yahoo.comInvitae to Present at the William Blair 43rd Annual Growth Stock ConferenceMay 26, 2023 | finance.yahoo.comNew Research Insights to be Presented by Invitae at the 2023 ASCO Annual Meeting Reinforce the Critical Role of Germline Genetic Testing in OncologyMay 26, 2023 | msn.comInvitae CFO Wen resigning to pursue other opportunities, appoints Christine Gorjanc as interim CFOMay 25, 2023 | finance.yahoo.comInvitae Announces CFO Transition and Selection of Veteran Finance Executive Christine Gorjanc as Interim CFOMay 21, 2023 | americanbankingnews.comInvitae Co. (NYSE:NVTA) CAO Sells $25,870.80 in StockJune 8, 2023 | Edge On The Street (Ad)Graphite Shortage Could Derail the $7 Trillion EV TransitionGraphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.May 20, 2023 | americanbankingnews.comInsider Selling: Invitae Co. (NYSE:NVTA) Insider Sells 26,476 Shares of StockMay 20, 2023 | americanbankingnews.comYafei Wen Sells 43,452 Shares of Invitae Co. (NYSE:NVTA) StockMay 20, 2023 | americanbankingnews.comInvitae Co. (NYSE:NVTA) CEO Sells $54,518.40 in StockMay 19, 2023 | americanbankingnews.comBrokers Offer Predictions for Invitae Co.'s Q2 2023 Earnings (NYSE:NVTA)May 18, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Invitae (NYSE:NVTA)May 17, 2023 | americanbankingnews.comRaymond James Downgrades Invitae (NYSE:NVTA) to UnderperformMay 15, 2023 | finance.yahoo.comInvitae to Appeal Trial VerdictMay 15, 2023 | msn.comRaymond James Downgrades Invitae (NVTA)May 15, 2023 | americanbankingnews.comInvitae (NYSE:NVTA) Given New $1.50 Price Target at Piper SandlerMay 14, 2023 | americanbankingnews.comInvitae Co. (NYSE:NVTA) Given Average Rating of "Hold" by AnalystsMay 12, 2023 | 247wallst.comGoldman Sachs Maintains Invitae Sell RecommendationMay 11, 2023 | msn.comGoldman Sachs Maintains Invitae (NVTA) Sell RecommendationMay 11, 2023 | seekingalpha.comInvitae down 11% after hours despite quarterly beatsMay 10, 2023 | finanznachrichten.deInvitae Corporation: Invitae Reports First Quarter 2023 Financial ResultsMay 10, 2023 | yahoo.comInvitae Reports First Quarter 2023 Financial ResultsMay 9, 2023 | finance.yahoo.comInvitae (NVTA) Q1 2023 Earnings Call TranscriptMay 8, 2023 | americanbankingnews.comInvitae (NVTA) to Release Quarterly Earnings on TuesdayMay 4, 2023 | americanbankingnews.comHead-To-Head Analysis: Invitae (NYSE:NVTA) & Biodesix (NASDAQ:BDSX)See More Headlines NVTA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NVTA Company Calendar Last Earnings5/09/2023Today6/08/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNYSE:NVTA CUSIPN/A CIK1501134 Webwww.invitae.com Phone(628) 213-3369FaxN/AEmployees1,700Year FoundedN/APrice Target and Rating Average Stock Price Forecast$3.88 High Stock Price Forecast$8.00 Low Stock Price Forecast$1.50 Forecasted Upside/Downside+226.3%Consensus RatingHold Rating Score (0-4)1.55 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($13.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,106,290,000.00 Net Margins-611.14% Pretax Margin-613.29% Return on Equity-285.28% Return on Assets-21.85% Debt Debt-to-Equity Ratio15.68 Current Ratio2.65 Quick Ratio2.55 Sales & Book Value Annual Sales$516.30 million Price / Sales0.60 Cash Flow$9.15 per share Price / Cash Flow0.13 Book Value$0.42 per share Price / Book2.83Miscellaneous Outstanding Shares260,670,000Free Float257,808,000Market Cap$310.20 million OptionableOptionable Beta1.75 Key ExecutivesDr. Randal W. Scott Ph.D. (Age 65)Co-Founder & Chairman Comp: $50kMr. Kenneth D. Knight (Age 62)Pres, CEO & Director Comp: $1.4MMs. Yafei Wen (Age 50)Chief Financial Officer Comp: $1.4MMr. Thomas R. Brida (Age 52)Gen. Counsel, Chief Compliance Officer & Sec. Comp: $776.72kMs. Hoki Luk (Age 47)Head of Investor Relations and Capital Markets Mr. Lee Bendekgey J.D. (Age 65)Chief Policy Officer Ms. Shelly D. Guyer (Age 63)Chief Sustainability Officer Ms. Desarie FrenchChief Talent OfficerDr. W. Michael Korn M.D.Chief Medical OfficerMr. Jackson J. Finks C.F.A.CFA, Director of Investor Relations & Strategic Fin.More ExecutivesKey CompetitorsCastle BiosciencesNASDAQ:CSTLCelcuityNASDAQ:CELCHH&L AcquisitionNYSE:HHLACareDxNASDAQ:CDNAPersonalisNASDAQ:PSNLView All CompetitorsInsiders & InstitutionsCapital Impact Advisors LLCBought 49,248 shares on 5/23/2023Ownership: 0.057%JPMorgan Chase & Co.Bought 10,397 shares on 5/18/2023Ownership: 0.743%New York State Common Retirement FundSold 41,399 shares on 5/18/2023Ownership: 0.048%Kenneth D KnightSold 45,432 sharesTotal: $54,518.40 ($1.20/share)Yafei WenSold 43,452 sharesTotal: $86,469.48 ($1.99/share)View All Insider TransactionsView All Institutional Transactions NVTA Stock - Frequently Asked Questions Should I buy or sell Invitae stock right now? 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Invitae in the last twelve months. There are currently 5 sell ratings and 6 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NVTA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVTA, but not buy additional shares or sell existing shares. View NVTA analyst ratings or view top-rated stocks. What is Invitae's stock price forecast for 2023? 11 Wall Street research analysts have issued twelve-month price objectives for Invitae's stock. Their NVTA share price forecasts range from $1.50 to $8.00. On average, they anticipate the company's share price to reach $3.88 in the next twelve months. This suggests a possible upside of 226.3% from the stock's current price. View analysts price targets for NVTA or view top-rated stocks among Wall Street analysts. How have NVTA shares performed in 2023? Invitae's stock was trading at $1.86 at the beginning of 2023. Since then, NVTA shares have decreased by 36.0% and is now trading at $1.19. View the best growth stocks for 2023 here. When is Invitae's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our NVTA earnings forecast. How were Invitae's earnings last quarter? Invitae Co. (NYSE:NVTA) released its quarterly earnings results on Tuesday, May, 9th. The medical research company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.41) by $0.04. The medical research company earned $117.36 million during the quarter, compared to analyst estimates of $116.57 million. Invitae had a negative net margin of 611.14% and a negative trailing twelve-month return on equity of 285.28%. The company's quarterly revenue was down 5.1% on a year-over-year basis. During the same period in the previous year, the company earned ($0.78) EPS. What ETFs hold Invitae's stock? ETFs with the largest weight of Invitae (NYSE:NVTA) stock in their portfolio include SPDR S&P Health Care Services ETF (XHS), Direxion Moonshot Innovators ETF (MOON), iShares Genomics Immunology and Healthcare ETF (IDNA), ARK Genomic Revolution ETF (ARKG), AXS Green Alpha ETF (NXTE), Global X Genomics & Biotechnology ETF (GNOM), Global X Telemedicine & Digital Health ETF (EDOC) and ARK Innovation ETF (ARKK). What guidance has Invitae issued on next quarter's earnings? Invitae updated its FY 2023 earnings guidance on Tuesday, May, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $500.00M-, compared to the consensus revenue estimate of $504.52 million. What is Sean George's approval rating as Invitae's CEO? 59 employees have rated Invitae Chief Executive Officer Sean George on Glassdoor.com. Sean George has an approval rating of 87% among the company's employees. What other stocks do shareholders of Invitae own? Based on aggregate information from My MarketBeat watchlists, some companies that other Invitae investors own include NVIDIA (NVDA), Block (SQ), Roku (ROKU), Tesla (TSLA), Alibaba Group (BABA), Trade Desk (TTD), Shopify (SHOP), Salesforce (CRM), Advanced Micro Devices (AMD) and Okta (OKTA). When did Invitae IPO? (NVTA) raised $76 million in an initial public offering (IPO) on Thursday, February 12th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan acted as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers. What is Invitae's stock symbol? Invitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA." Who are Invitae's major shareholders? Invitae's stock is owned by many different retail and institutional investors. Top institutional investors include ARK Investment Management LLC (12.78%), BlackRock Inc. (8.45%), Sumitomo Mitsui Trust Holdings Inc. (6.92%), Nikko Asset Management Americas Inc. (6.92%), Baker BROS. Advisors LP (3.41%) and State Street Corp (3.17%). Insiders that own company stock include Artur Bergman, E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Jason W Myers, Katherine Stueland, Kenneth D Knight, Robert F Werner, Robert F Werner, Robert L Nussbaum, Robert L Nussbaum, Sean E George, Sean E George, Shelly D Guyer, Thomas Brida and Yafei Wen. View institutional ownership trends. How do I buy shares of Invitae? Shares of NVTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Invitae's stock price today? One share of NVTA stock can currently be purchased for approximately $1.19. How much money does Invitae make? Invitae (NYSE:NVTA) has a market capitalization of $310.20 million and generates $516.30 million in revenue each year. The medical research company earns $-3,106,290,000.00 in net income (profit) each year or ($13.32) on an earnings per share basis. How many employees does Invitae have? The company employs 1,700 workers across the globe. How can I contact Invitae? Invitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The official website for the company is www.invitae.com. The medical research company can be reached via phone at (628) 213-3369 or via email at ir@invitae.com. This page (NYSE:NVTA) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invitae Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.